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Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cyclic AMP-activated chloride channel comprising
two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs) and a unique regulatory (R) domain.
The most frequent cystic fibrosis (CF) mutation, a deletion of Phe508 in NBD1, results in the retention of the vF508 CFTR
in the endoplasmic reticulum, as do many other natural or constructed mutations located within the first NBD. In order to
further define the role of NBD1 in CFTR folding and to determine whether the higher frequency of mutations in NBD1 with
respect to NBD2 results from its position in the molecule or is related to its primary sequence, we constructed and expressed
chimeric CFTRs wherein NBD domains were either exchanged or deleted. Synthesis, maturation and activity of the chimeras
were assessed by Western blotting and iodide efflux assay after transient or stable expression in COS-1 or CHO cells
respectively. The data showed that deletion of NBD1 prevented transport of CFTR to the cytoplasmic membrane whereas
deletion of NBD2 did not impair this process but resulted in an inactive chloride channel. On the other hand, substituting or
inverting NBDs in the CFTR molecule impaired its processing. In addition, while the NBD1 R555K mutation is known to
partially correct the processing of CFTR vF508 and to increase activity of both wild-type and vF508 individual channels, it
showed no positive effect when introduced into the double NBD1 chimera. Taken together, these observations suggest that
the proper folding process of CFTR results from complex interactions between NBDs and their surrounding domains (MSDs
and/or R domain). ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Cystic ¢brosis transmembrane conductance regulator; Chloride channel; Nucleotide binding domain; Chimeric recombinant
protein
1. Introduction
The cystic ¢brosis transmembrane conductance
regulator (CFTR) is a cAMP-activated chloride
channel that resides at the luminal surfaces and in
endosomes of epithelial cells from airways, intestine,
and a variety of exocrine glands.
This ion channel is regulated by phosphorylation
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and by intracellular nucleotides (for reviews see [1^
3]).
The current model of CFTR secondary structure
[4] comprises ¢ve domains. The basic unit consists of
six membrane-spanning K-helices forming a mem-
brane-spanning domain (MSD), and a cytoplasmic
nucleotide binding domain (NBD) comprising at
least three consensus sequences: the Walker A and
Walker B motifs [5] and a glutamine-rich sequence
(LSGGQ) called the linker peptide [6], signature mo-
tif or motif C [7]. Two of these units are separated by
a cytoplasmic regulatory (R) domain containing mul-
tiple potential phosphorylation sites. The canonical
structure of the two MSDs and the two NBDs places
CFTR in the superfamily of membrane proteins
called tra⁄c ATPases [8] or ABC (ATP binding cas-
sette) transporters [9]. The presence of a large regu-
latory domain is a feature that distinguishes CFTR
from other members of the family.
Previous studies have provided some insight into
the structure and function of individual domains of
CFTR. Indeed, patch-clamp analysis of mutant
CFTR indicated that residues within the MSDs con-
tribute to the formation of the Cl3 channel pore [10^
12] and that phosphorylation of the R domain by the
cAMP- dependent protein kinase A (PKA) was re-
quired for channel opening [13^15]. ATP further reg-
ulates the channel activity through interaction with
the two cytoplasmic NBDs. The study of speci¢c
mutants suggested that CFTR Cl3 channels are ei-
ther activated or primed for activation by ATP hy-
drolysis at NBD1, whereas the duration of channel
activation was controlled by hydrolysis of ATP
bound at NBD2 [1,2,16,17]. Other observations led
to the suggestion that the NBDs were partially in-
serted into the plasma membrane, potentially form-
ing a portion of the CFTR-conducting pore [18^21].
Complex physical interactions between these do-
mains are thus required for the regulation of the
CFTR activity and NBD1 and NBD2 may not be
equivalent in this respect. Nevertheless, the CFTR
truncation mutant (D836X), which contains the ¢rst
MSD, NBD1, and the R domain, is capable of form-
ing regulated Cl3 channels when expressed in HeLa
cells [22] and the protein was shown to cosediment
with mature CFTR on a sucrose gradient, suggesting
that this ¢rst half of the CFTR forms homodimers.
On the other hand, Devidas et al. [23] have recently
shown that constructs containing the second half of
the CFTR (R domain, MSD2 and NBD2) form con-
stitutively opened chloride channels. Taken together,
these studies suggest that NBD1 can play a similar
role as NBD2 and conversely.
In the present work, we addressed the question of
interchangeability and position e¡ect of NBDs in the
CFTR molecule with respect to folding, tra⁄cking to
the membrane and activity of the channel. To this
end, a set of chimeras was constructed, expressed in
mammalian cells and characterized in terms of mem-
brane insertion and cAMP-stimulated Cl3 channel
activity.
2. Materials and methods
2.1. Materials
DNA modifying and restriction enzymes were pur-
chased from Boehringer Mannheim or Gibco BRL,
and used essentially as described by the manufac-
turer. Ligations were achieved by the rapid DNA
ligation kit from Boehringer Mannheim. PCR was
performed with a Cetus apparatus and the Pwo
polymerase from Boehringer. Oligodeoxyribonucleo-
tides were synthesized on an Applied Biosystems syn-
thesizer model 380A via the solid-phase phosphor-
amide method. Cell culture media, L-glutamine,
fetal calf serum (FCS) and antibiotics were pur-
chased from Gibco BRL. All chemicals were from
Sigma.
2.2. Methods
2.2.1. Construction of CFTR 4M and CFTR 4MN
The CFTR coding region was isolated from the
eukaryotic vector pTG5985 (a kind gift from Dr Pa-
virani, Transgene S.A., Strasbourg, France) and in-
troduced into pNIV103, a multicloning site plasmid
developed in this laboratory. CFTR 4M and CFTR
4MN coding sequences were constructed in order to
allow the removal or insertion of NBD coding se-
quences according to di¡erent boundaries of these
domains.
For this purpose, restriction sites were introduced
by PCR mutagenesis [24] at the edges of the NBDs:
SnaBI and BsrBI £anking NBD1 and Eco47III and
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EheI £anking NBD2 in CFTR 4M, while in CFTR
4MN EheI and Eco47III £ank NBD1 and SwaI and
PmeI £ank NBD2 in CFTR 4MN (see Table 1 for
primer sequences). Position and sequence of the mu-
tated bases are indicated in Fig. 1A.
The CFTR 4M and CFTR 4MN cDNAs, as well
as the wild-type and vF508 CFTR cDNAs, were in-
serted in the pTND expression vector (a derivative of
pTDN [25]) under the control of the Rous sarcoma
virus LTR promoter. This was achieved through the
isolation of a AvaI 4500 bp fragment and ligation
between the HindIII and BclI sites of the vector
with two adapters (see Table 1 for the adapter se-
quences). The resulting plasmids (pNIV4923 with
CFTR 4M or pNIV4943 with CFTR 4MN) were
used to transfect COS-1 or CHO cells (Fig. 1B).
2.2.2. Construction of other variant and mutant
CFTR cDNAs
Starting from pTND CFTR 4M (pNIV4923) and
pTND CFTR 4MN (pNIV4943), we constructed
plasmids encoding molecules in which the NBD do-
mains were either substituted, duplicated or deleted.
This was achieved through restriction by enzymes
corresponding to the introduced sites and ligation
into the pTND CFTR 4M and pTND CFTR 4MN
plasmids.
2.2.3. Cell culture and transient transfection of COS-1
cells
COS-1 cells (ATCC: CRL 1650) were grown at
37‡C with 5% CO2 in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% FCS, L-glutamine
and antibiotics. Cells were transfected at a subcon-
£uent stage by the calcium phosphate coprecipitation
procedure [26] with 15 Wg/ml of plasmid DNA. The
medium was replaced after 16 h. Protein expression
was assayed 48 h after transfection. When necessary,
cells were collected by trypsinization 24 h after trans-
fection, pooled and reseeded to appropriate dishes.
Table 1
Sequences of the various oligonucleotides used in PCR and site-directed mutagenesis
Oligonucleotide Sequence Positiona
M28 5P-GAATCATCCTCCGGAAAATATTCACC-3P 1121 s
M29 5P-CCTTGGTTAACTGAGTGTGTCATCAGG-3P 2471 a
M30 5P-GAGAATTCACACGTGAAGAAAGATGAC-3P 3712 s
M31 5P-CGAGGGCCGGATCTGCAGTTATGCTGC-3P 4587 (+18) a
M83 5P-CCTGATGACACACTCAGTTAACCAAGG-3P 2445 a
M24 5P-GTGAGAAATTTACGTAGAAGAGGCTG-3P 1433 a
M20 5P-GTTTTAACAGAGCGGGAAATATTTG-3P 1870 s
M26 5P-CTGTGTATTTAGCGCTGAGATCTTTG-3P 3793 a
M82 5P-CTTTCGACCAATTTAGCGCTGAAAGAAG-3P 2078 s
M22 5P-GTAACATACCAAGGCGCCAGAAGAACTC-3P 4267 s
M81 5P-CCTGTATTTTGTTTATGGCGCCAAGAGA-3P 1249 a
M84 5P-GGCATGTCAATGAATTTAAATACTCGGC-3P 3641 a





M28 and M29 for NBD1 ampli¢cation and replacement (as a BspEI-HpaI 1333 bp fragment).
M30 and M31 for NBD2 ampli¢cation and replacement (as a PmlI-PstI 868 bp fragment).
M83 and M31 for NBD2 ampli¢cation and replacement (as a HpaI-PstI 2160 bp fragment).
Primers for PCR mutagenesis : SnaBI site was constructed using primer M24, BsrBI using M20, Eco47III using M26 (for CFTR 4M)
or M82 (for CFTR 4MN), EheI using M22 (for CFTR 4M) or M81 (for CFTR 4MN), SwaI using M84 and PmeI using M85.
Primers for isolation and cloning of the CFTR cDNA as a AvaI 4500 bp fragment: M1-M2 (to construct a HindIII-EcoRV-SacII-
AvaI adapter at the 5P end) and M13-M14 (to construct an AvaI-EcoRI-SacII-BclI adapter at the 3P end).
Sites involved in mutagenesis are underlined.
aPosition of the primers with respect to the sequence of the CFTR cDNA as published in [4]. s, coding sequence; a, non-coding se-
quence.
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2.2.4. Cell culture and transfection of CHO cells
Chinese hamster ovary (CHO) cells DG44 dhfr3
(ATCC: CRL) were maintained at 37‡C with 5%
CO2, in F12 medium supplemented with 5% FCS,
L-glutamine and antibiotics. At a subcon£uent stage,
cells were transfected by electroporation (15 Wg of
linearized plasmid DNA/107 cells). Transfectants
were selected in medium containing 50 Wg/ml of
G418, and pools of resistant clones were further am-
pli¢ed with 20 WM methotrexate. After 15 days, sur-
viving individual colonies were picked and ampli¢ed
in selective medium (4^10 clones were tested for each
construct).
2.2.5. Cell membrane puri¢cation
Transfected cells were pelleted, washed and incu-
bated for 30 min at 4‡C into hypotonic bu¡er (1 mM
NaHCO3) with the following protease inhibitors:
1 WM PMSF, 25 mM iodoacetamide, 2.5 mM N-
ethylmaleimide, 2.5 mM 1,10-phenanthroline, 2.5
mg/ml soybean trypsin inhibitor I-S and 0.5 Wg/ml
leupeptin. Cell lysate was centrifuged for 15 min at
3000 rpm to remove nuclei and non-lysed cells; the
supernatant was again centrifuged for 20 min at
20 000 rpm. Pelleted membranes were dissolved in
10 mM HEPES, 250 mM mannitol, pH 7.5 with
the same antiproteases. Each sample was assayed
for protein concentration by a protein assay kit
(Bio-Rad DC protein assay kit).
2.2.6. Immunodetection of CFTR
Membrane samples (40 Wg) were denatured with
2-fold concentrated PAGE loading bu¡er (Tris-HCl
0.125 M pH 6.8, glycerol 20%, SDS 40%, bromophe-
nol blue, antiproteases) and subjected to SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE) on 7.5%
separating gels. After electroblotting of proteins on
nitrocellulose ¢lters (ECL-Hybond nitrocellulose
membrane, Amersham), membranes were saturated
with 5% non-fat dried milk in TBS (Tris 0.02 M,
pH 7.5, NaCl 0.15 M) containing 0.1% Tween 20
(TBS-T) and further incubated for 2 h with anti-hu-
man CFTR monoclonal antibody raised against the
carboxy-terminal four amino acids (from Genzyme,
code 2503-01, dilution of 1:1000) or R domain spe-
ci¢c (MATG 1104 from Transgene S.A., dilution of
1:1000) both in TBS-T with 5% non-fat dried milk,
for 1 h with biotinylated anti-mouse immunoglobu-
lins (Amersham, 1/4000 in TBS-T) and 30 min with
streptavidin-biotinylated horseradish peroxidase
complex (Amersham, 1/4000 in TBS-T). Proteins
were detected by enhanced chemiluminescence
(ECL Western blotting kit, Amersham) according
to the manufacturer’s instructions.
2.2.7. Iodide e¥ux assay
The iodide e¥ux assay described previously for
CFTR-transfected CHO cells [27] was slightly modi-
¢ed. Cells were loaded for 1 h at room temperature
with loading bu¡er (136 mM NaI, 3 mM KNO3,
2 mM Ca(NO3)2, 11 mM glucose and 20 mM
HEPES, pH 7.4) containing 5 WCi/ml of 125I. Extra-
cellular NaI was washed away thoroughly (six times)
with e¥ux bu¡er (136 mM NaNO3 replacing 136 mM
NaI in the loading bu¡er) and cells were equilibrated
for 1 min in a ¢nal 1 ml aliquot.
The ¢rst three aliquots were used to establish the
baseline in e¥ux bu¡er alone. Agonists (10 WM for-
skolin, 200 WM dibutyryl-cAMP, and 1 mM 3-isobu-
tyl-1- methylxanthine (IBMX), dissolved in dimethyl
sulfoxide) were added to the e¥ux bu¡er at time
zero. The same amount of dimethyl sulfoxide with-
out agonists was added to the e¥ux bu¡er in the
control samples. The amount of 125I in each aliquot
(1 ml) was counted and the e¥ux rate of iodide for
each time point was calculated in relation to the
iodide remaining in cells.
3. Results
To address the question of whether the functional
di¡erences observed between the two NBDs in
CFTR as well as the high frequency of mutations
in NBD1 were mainly due to sequence or positional
e¡ects, we constructed a series of chimeric derivatives
in which we moved or deleted the NBD domains.
During the course of this study, three new struc-
tural models of the ¢rst NBD were proposed. These
models were based on the crystal structure of bovine
mitochondrial F1-ATPase [7,28] and on the model of
the large domain of aspartate aminotransferase [29].
They predicted a similar fold of NBD1 and led to
reconsideration of the boundaries, especially the C-
terminal limit which was initially de¢ned by the end
of exon 12 [4]. The NBD1 forms a classical Rossman
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Fig. 1. Construction of CFTR variants (CFTR 4M and CFTR 4MN) containing unique restriction sites at di¡erent boundaries of
NBD1 and NBD2. (A) SnaBI, BsrBI, Eco47III, EheI, SwaI and PmeI were introduced at the borders of NBD1 and NBD2 by site-di-
rected mutagenesis using oligonucleotides containing the mutations. (B) Schematic diagram of the eukaryotic expression vector con-
taining CFTR 4M or CFTR 4MN constructs ( = pNIV4923 or pNIV4943 respectively) and the position of the relevant restriction sites
used for the study. Expression of CFTR 4M and CFTR 4MN is under the control of the Rous-LTR promoter. The original vector
(pTND) also contains a mutant dihydrofolate reductase (DHFR) gene under the control of the SV40 early promoter, allowing for se-
lection of transfectants with methotrexate.
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Fig. 2. Schematic structure of variant CFTRs used in this study. A representation of the domains present in wild-type CFTR is shown
at the top, and constructs are indicated below. The molecules are modelled with the MSDs shown as shaded boxes, the NBD1 as a
white box, the NBD2 as checked boxes and the R domain as a black oval. Deletions are indicated as a stippled line, no linker se-
quences were added. Concerning the CFTR 4M construct and its variants, NBD1 contained amino acids 431^583, and NBD2 con-
tained amino acids 1217^1383. With regard to the CFTR 4MN construct and its variants, NBD1 contained amino acids 367^654, and
NBD2 contained amino acids 1165^1450.
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fold consisting of a central L-sheet surrounded by
helices on both sides, and the N-terminus of the R
domain (originally de¢ned as amino acids 590^831,
encoded by exon 13 [4]) may be part of this central L-
sheet. In these models, the two L-strands formed by
residues in the initial N-terminus of the R domain
are predicted to lie in close proximity to the Walker
A, which is thought to be critical for ATP binding
and/or hydrolysis in ABC transporters [4,28,29].
Therefore, we considered the two possible bounda-
ries of NBD1 and, by sequence alignments, of NBD2
for our constructions.
To facilitate deletions and shu¥ing, we ¢rst con-
structed two CFTR cDNA variants, each containing
four unique restriction sites at the supposed borders
of NBD1 and NBD2 (CFTR 4M and CFTR 4MN,
Fig. 1A).
The four restriction sites introduced by PCR mu-
tagenesis in the CFTR 4M variant are close to the
initial limits of the NBDs as de¢ned by Riordan et
al. [4]. By design, this led to six unavoidable amino
acid substitutions chosen to be as conservative as
possible. Restriction sites were engineered 27 residues
upstream of the Walker A domain and 13 residues
downstream of the Walker B domain. From this
construct, NBD1 and NBD2 could therefore be iso-
lated respectively as a blunt SnaBI-BsrBI (codons
431^583) and as an Eco47III-EheI blunt fragment
(codons 1217^1383).
In the CFTR 4MN variant, the four unique re-
striction sites were engineered close to the boundaries
of the NBDs as de¢ned by the more recent structural
models [7,28,29]. These restriction sites were intro-
duced without a¡ecting the amino acid sequence, ex-
cept for PmeI which led to an unavoidable amino
acid substitution after the C-terminal limit of the
NBD2. From this CFTR 4MN, NBD1 and NBD2
could therefore be isolated respectively as an EheI-
Eco47III blunt fragment (codons 367^654) and as a
SwaI-PmeI blunt fragment (codons 1165^1450).
The cDNAs encoding wild-type (wt), vF508,
CFTR 4M and CFTR 4MN variants were inserted
into the pTND eukaryotic expression vector down-
stream of the RSV-LTR promoter (Fig. 1B) and
transfected into COS-1 and CHO cells. As newly
synthesized non-glycosylated wild-type CFTR is
known to migrate at V130 kDa (band A), core gly-
cosylated CFTR found in the endoplasmic reticulum
(ER) and Golgi at V135 kDa (band B) and mature
protein as a broad band at approximately 170 kDa
(band C), these three typical products were searched
for and compared by Western blotting.
Wild-type CFTR, CFTR 4M and CFTR 4MN
presented essentially the same pattern (Fig. 3, lanes
2, 4 and 5) in contrast to vF508 CFTR (Fig. 3, lane
3) for which only bands A and B were observed. This
indicated that the engineering of CFTR 4M and
CFTR 4MN did not a¡ect the processing or the
tra⁄cking of the molecule to the cell membrane.
Furthermore, on the basis of an iodide e¥ux assay,
Fig. 3. Immunodetection of CFTR variants in COS-1 cells. Using the expression vector pTND, control (vector only), wild-type, chi-
meric or mutant CFTR proteins were transiently expressed in COS-1 cells for 48 h. A membrane-enriched preparation from trans-
fected cells was prepared and 40 Wg of total protein was analyzed by Western blotting (see Section 2). Migration of Mr (U1033)
markers is shown on the left. The positions of the unglycosylated (band A), core-glycosylated (band B) and fully glycosylated (band
C) forms of CFTR are indicated. Bands AP, BP and CP represent the same forms for the vNBD variants.
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it appeared that these CFTR variants were as active
as the wild-type CFTR (Fig. 4).
In view of these results, CFTR 4M and CFTR
4MN cDNAs were used as a starting point for the
construction of the variants which are schematically
depicted in Fig. 2.
pNIV4924 (with initial limits of NBDs) and
pNIV4947 (with extended limits of NBDs) encode
CFTR molecules wherein NBD2 has been replaced
by NBD1 (CFTR 2UNBD1). The rationale for such
a construct was that the closing probability of the
channel would be di¡erent if the involvement of
NBD2 in this process resulted from its sequence or
from its position in the molecule.
The same rationale applied to the channel opening
probability for pNIV4931 (initial limits) and
pNIV4948 (extended limits) which encode molecules
wherein NBD1 was replaced by NBD2 (CFTR
2UNBD2), and for pNIV4930 (initial limits) and
pNIV4949 (extended limits) which specify a NBD2/
NBD1 variant forms of CFTR.
Western blotting of COS-1 cells transfected with
these constructs showed that only bands A and B
were detected as for vF508 CFTR (Fig. 3, lanes 6^
11), suggesting that the variant molecules were not
Fig. 4. cAMP-stimulated iodide e¥ux from CHO cells express-
ing wild-type and variant CFTRs. (A) Processing of wild-type
and mutant CFTRs expressed in CHO cells. A membrane-
enriched preparation from transfected cells was prepared and
40 Wg of total protein was analyzed by Western blotting, as
described in Section 2. Lanes: 1 = CHO-mock-transfected,
2 = CHO-CFTR WT, 3 = CHO-CFTR 4M, 4 = CHO-CFTR
R555K, 5 = CHO-vNBD2 and 6 = T84 cell line as positive con-
trol (derived from human gastrointestinal tract and expressed
naturally CFTR protein). (B) Iodide e¥ux assays were per-
formed on con£uent CHO cells (as negative control) grown on
a plastic support and on CHO cells expressing CFTR WT,
CFTR 4M, CFTR 4M-vNBD2 and CFTR 4M-R555K mole-
cules. Activation of PKA was evoked, as described in Section
2, by addition of an agonist cocktail ( = Ag+) to the e¥ux me-
dium at the 0 min time point. The same amount of dimethyl
sulfoxide without agonists ( = Ag3) was added to the e¥ux
bu¡er in the control samples. The amount of radioactive iodide
in successive 1 ml aliquots was counted and the e¥ux rate of
iodide was calculated in relation to the amount remaining in
cells at each time. The pro¢les of all the control samples ‘Ag3’
were similar, therefore only the e¥ux curve for CFTR WT is
represented in this ¢gure. Representative results of three inde-
pendent experiments are shown. Data points are means of trip-
licates with S.E.M.
Table 2
Expression, maturation and activity of the CFTR variants used
in this study
CFTR variant Protein Function
A B C
Wild-type + + + +
vF508 3 + 3 3
4M + + + +
4MN + + + +
4M-2UNBD1 3 + 3 3
4MN-2UNBD1 3 + 3 3
4M-R555K 3 + + +
4M-2U(NBD1+R555K) 3 + 3 3
4M-NBD2/NBD1 3 + 3 3
4MN-NBD2/NBD1 3 + 3 3
4M-2UNBD2 3 + 3 3
4MN-2UNBD2 3 + 3 3
4MvNBD1 + + 3 3
4MvNBD2 + + + 3
+ indicates the presence and 3 the absence of a CFTR band of
the size expected for the A, B and C forms in transiently ex-
pressing COS-1 cells. Functional CFTR Cl3 channels was de-
termined by the iodide e¥ux assay as described in Section 2.
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correctly folded and were trapped in the ER or Golgi
network. The choice of the initial limits or the
extended limits of NBDs had no in£uence on the
processing and the tra⁄cking of these chimeric
molecules.
To further determine whether the misfolding of
2UNBD1 molecule resulted from the additive e¡ect
of the NBD1 intrinsic instability, we looked for a
reversion of this phenotype by the R555K mutation.
This mutation on NBD1 corrected the processing
abnormality of CFTR vF508 and enhanced the ac-
tivity of vF508 and wild-type individual proteins by
increasing burst duration [30]. The R555K mutation
was then introduced into each NBD1 of the
2UNBD1 variant. Plasmid pNIV4929 encoding
such a molecule was transfected in COS-1 cells and
proteins were analyzed by Western blotting. Fig. 3,
lane 15, shows that the R555K mutation did not
reverse the processing block observed for the
2UNBD1 molecule, suggesting that this defect did
not result from an additive e¡ect of the intrinsic
NBD1 instability.
The tra⁄cking defect that we also observed for
2UNBD2 and NBD2/NBD1 molecules could poten-
tially result from a defect in NBD-MSD or NBD-R
domain interactions.
To further investigate the respective roles of
NBD1 and NBD2 in the tra⁄cking and folding of
the protein we constructed molecules deleted of ei-
ther NBD1 or NBD2 domains (vNBD1 CFTR en-
coded by pNIV4933 and vNBD2 CFTR encoded by
pNIV4932).
For the vNBD1 CFTR, only the B form of the
molecule was detected (Fig. 3, lane 12). This mutant
was thus restricted to the ER and was not correctly
tra⁄cked to the plasma membrane. This result seems
to contradict previous observations [31] although
these authors analyzed a molecule containing a dele-
tion encompassing more than the NBD1 itself (co-
dons 404^589, i.e. exons 9^12).
In contrast, we observed a fully glycosylated form
for the vNBD2 CFTR (Fig. 3, lane 13). The mole-
cule nevertheless proved devoid of chloride channel
activity (Fig. 4), a result which is in agreement with
the observations made by others [31] on a mutant
containing a larger deletion including the complete
NBD2 (codons 1157^1414, i.e. exons 18^22).
Results concerning expression, maturation and ac-
tivity of the di¡erent chimeric and mutant CFTRs
involved in this study are summarized in Table 2.
4. Discussion
The CFTR molecule may be described as a dimer,
each monomer containing a membrane-spanning do-
main and a nucleotide binding domain, linked to-
gether by a regulatory domain.
This simple view, however, does not take into ac-
count potential di¡erences in NBD1 and NBD2
structure, function, and interactions with their re-
spective MSDs although they have been shown to
play a di¡erent role in channel opening and closing
[1,2,16,17].
The present study was undertaken to determine
whether this speci¢city of e¡ects resulted mainly
from di¡erences in primary sequences (percent iden-
tical residues between NBD1 and NBD2: 33%) or
from positional e¡ects.
Starting from engineered, correctly processed and
fully active CFTR variants (CFTR 4M and CFTR
4MN), it was possible to construct plasmids encod-
ing CFTR chimeras containing either two NBD1,
two NBD2 or exchanged NBD domains. None of
these molecules, when expressed in mammalian cells,
was correctly processed. These results were similar
when the chimeric molecules were constructed in
consideration of initial or extended boundaries of
NBDs. Consequently, the absence of correct process-
ing is not due to the displacement of incomplete do-
mains.
In addition, the R555K mutation, known to re-
verse the processing abnormality due to the vF508
mutation, did not restore the processing of the
2UNBD1 variant. This result suggests that the defect
in the tra⁄cking of the double NBD1 form may not
be understood as resulting from the intrinsic insta-
bility of this domain, but more probably from an
inappropriate interaction of the NBD1 sequence
with the surrounding sequences at the NBD2 locus.
Our results bring some insights into the mecha-
nisms underlying the intracellular CFTR processing.
Two possibilities seem to be the most probable. Ei-
ther the two NBDs are not equivalent with respect to
their role in the processing of the whole CFTR, or
both NBD1 and NBD2 perform the same role in the
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processing, but within a speci¢c environment and
interactions provided by the sequence context of
each half-molecule. This latter explanation is rein-
forced by the observation that separate expression
of the two halves of the CFTR (MSD1-NBD1-R
domain and R domain-MSD2-NBD2 or only
MSD2-NBD2) forms two molecules e⁄ciently traf-
¢cked to the plasma membrane and functional chan-
nels. Furthermore, some subunit-subunit interactions
between the NBDs and their neighboring domains
are supposed to be essential for the structure and/
or the function of the channel, like LSGGQ motifs
mediating an interaction between the NBDs and the
MSDs [9,28], or an interaction between the R do-
main and NBD1 [32].
On the other hand, a CFTR variant lacking NBD2
was e⁄ciently transferred to the plasma membrane
whereas its NBD1-deleted equivalent was not. This
result suggests that the presence of NBD1, its stabil-
ity and its correct folding are more important than
NBD2 for an e⁄cient processing of the whole chan-
nel. Nevertheless, as for CFTR vNBD1, the lack of
NBD2 failed to generate a functional CFTR chloride
channel.
Taken together, these results suggest that despite
the dominant role of NBD1, the key points for a
correct folding process of the molecule are the com-
plex interactions between the nucleotide binding do-
mains and their neighboring domains (MSDs and/or
R domain).
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